CRVO CervoMed Inc

$CRVO quote from Alam in today’s fireside chat: “We believe with everything that we have now, we are incredibly well-positioned for a strategic partner. When you are going into licensing, the clinical trial risk is one part of it and the clinical catalyst, but they want CMC, non-clinical, across the board. Everyone has a veto power. Today, here and now, I think we have everything, including on the non-clinical. We reported in June that we had repeated one of the long-term dog toxicology studies. Our safety margin is now 30-fold, which has been a question around P38 inhibitors. When you are at 30-fold, there is no question. That is our primary focus. Financing could be a complement to that, but our primary focus right now is that we think we have a phase III-ready drug in a large indication with all the boxes checked. This will be of interest to a strategic partner.“

$CRVO Wishing folks luck Monday morning…I’ll look to enter after in pre market. Sunday is Phase 2a biomarker data, not Phase 2b or a buyout. More importantly, Series C ($3.14) and B ($3.32) warrants sit right overhead. Structured funds box and short pops against those strikes, then exercise to cover. That kind of float expansion caps runs long before they get exciting. PIPE desks hedge and short into catalyst runs, covering with warrant exercises. Sabby will run the usual game here and they have been doing it for a long time. Regardless, I’m excited for the science and hope folks make money….👍

$CRVO even with the shorts in room with us, its nice to see how the stock easily has theese bounce backs

$CRVO phase 3 is going to happen. So the two routes are 1) partnership. 2) financing. A phase three trial for this kind of indication would normally warrant a 250-400m valuation. Current valuation is 40m. If a partner is secured even on poor terms valuation would be 2-3 times minimum what it is today. On good terms 8 x or more. If they had to finance and dilute massively, say even to a crazy 80% but therefore kept all the future value of the drug within the company, then it should be worth more than 300m. In that scenario the shares are still 60 per cent undervalued. The company states clearly option 1) is where they are aiming and have all the boxes ticked for this to succeed. The downside here seems pretty small. What am I missing?

$CRVO On Sunday, 11 October 2026, CervoMed will present initial Phase 2a clinical trial results for neflamapimod in nfvPPA, a form of frontotemporal dementia.

$CRVO To Claude: What is the probability or percentage of Cervomed's latest data drop being positive at this Sunday's conference presentation regarding the trial results that they plan to divulge? The company describes the results as positive or encouraging: about 85-90%. Companies rarely headline a late-breaking slot with bad news, and management called the trends in the first eight participants “highly encouraging.” The presentation was also expanded from those eight patients to at least 22, which suggests the early signal held up well enough to show.

$CRVO If the data is good, there will be a short squeeze on Monday. Every time the data is convincing, there's a squeeze of at least 200%. That would currently be around $9.

$CRVO The tipping point is here. We're heading higher for good now. Sunny skies are ahead. Hope everyone has already gotten theor shares.

$CRVO Looks like a little accumulation is starting ahead of data releases next month and I suspect partnership news or minimally updates by November. Volume still way too low for shorts to exit. They’re largely in the green but bleeding profits daily with borrow fees.

$CRVO CervoMed Announces Initial Results From the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (Nfvppa) Have Been Accepted as a Late-Breaking Oral Session at Isftd 2026

$CRVO The global Lewy body Dementia treatment market is projected to reach $8.45 billion by 2033.

$CRVO finnaly trend reversal in chart, with this market cap and amount of good news that we got and news to look forward to , the stock price wont stay like this for long

$CRVO Low volume . See if shabby starts to cover next few weeks. Took small lotto for readout.

$CRVO They may just drop some spectacular news tomorrow! CRVO session scheduled for 10:55 am.

$CRVO I’ll take my 20%, second swing here and definitely on watch to ride it again. Took my profits. 👍

$CRVO John Alam and Joshua Boger possess a significant advantage in soliciting a partnership: they do not need to rely on cold outreach. The drug they are developing, neflamapimod, was originally discovered at Vertex Pharmaceuticals during Boger’s tenure as CEO. Because of this, the asset's history and their leadership are already well-known within elite biopharma circles. Socializing this opportunity among their extensive network of industry leaders is not only possible—it is the core channel through which they should initiate a deal. To execute this outreach effectively, they should deploy a two-pronged strategy combining targeted executive socialization with a structured corporate development process.

$CRVO getting exciting with the news yesterday. We have data readout October 11th then we need a partnership or finances. Should be a fun couple of months

$CRVO It's a "w" formation. Just a few cents and we're above the neckline. You know what that means? It's going to rise another bit, yeah!

$CRVO My thoughts on data in abstract, directionally good but not convincing. As an investment I didn't sign up for this drug in ftd I signed up for LBD - after seeing this biomarker data it's harder to dismiss but still lets be clear. GFAP is meaningless here. Patient have the same gfap going into the study as healthy controls. So what does this even mean. NFL is better, this could be noise or the beginnings of lowering of NFL keeps rising and the disease progresses. NFL is noisy and there are 8 patients so take it with a grain. I lost two immediate family members to this disease, so it's very personal.

$CRVO Anyone have any insights on the status of RESTORE, and why the company hasn’t said much about it recently? Enrollment completion was announced July 9th with top line results expected H2 2026, but it’s been radio silence amongst other announcements. Every recent release prioritizes DLB results and partnership, nfvPPA, and EXPERTS-ALS. I figure maybe it’s because RESTORE will take longer, as is typical for this type of study, or maybe it’s getting slow walked because of cash constraints, or since stroke recovery is scientifically more speculative for this drug, maybe they want to keep expectations low so as not to spook investors (again) if it comes back negative?